What You Should Know:
- Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included participation from other institutional investors. The price per share was set at $0.43, representing a 17% premium over the 10-day volume-weighted average trading price.
- The funding will fuel the development of CYB003, a potential first-in-class psychedelic
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
AstraZeneca Acquires Fusion Pharmaceuticals for $2B to Bolster Radioconjugate Pipeline
What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
AstraZeneca's Acquisition of Fusion:
Read More
Komodo Launches Self-Service App for Pharma Research
What You Should Know:
Today, Komodo Health unveiled a new self-service solution for rapid patient cohort analysis and insight generation.MapView is the industry’s first and most sophisticated analytics application that allows users without data science expertise to easily extract insights from Komodo’s Healthcare Map. MapView is designed to accelerate decision-making across the Life Sciences enterprise by generating powerful, automated business intelligence for every team and
Read More
QDx Pathology Services Deploys Proscia’s Pathology Platform To Improve Speed & Precision
What You Should Know:
QDx Pathology Services, an independent anatomical, molecular, and clinical pathology laboratory serving medical professionals and facilities throughout the United States, is working with Proscia®, a leading provider of digital and computational pathology solutions, to innovate its practice.The laboratory has deployed Proscia’s software to enable its pathologists to work faster and more confidently.
Revolutionizing Pathology: Proscia's Digital Solutions
Read More
Tempus Donates Over 3,000 Cancer Patient Profiles to Fuel National Cancer Institute Research
What You Should Know:
- Tempus, a leader in artificial intelligence and precision medicine, announced a groundbreaking data contribution to the National Cancer Institute (NCI) today.
- The first-of-its-kind contribution will significantly enhance the NCI's planned Data Enclave, a secure repository designed to accelerate cancer research.
Unlocking Insights from 3,000 Cancer Diagnoses
Tempus is donating de-identified tumor profiles with limited associated clinical information from over
Read More
Zephyr AI Secures $111M to Democratize Precision Medicine with Explainable AI
What You Should Know:
- Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group.
- The company plans to use this round of funding to refine its technology to fortify its extensive collection of training and validation datasets, crucial for robust AI models, deliver results even faster, and expand its scientific and commercial
Read More
Pi Health Secures $30M to Democratize Cancer Clinical Trials
What You Should Know:
- Pi Health, a newly independent oncology-focused clinical research company raises $30M in Series A funding led by AlleyCorp and Obvious Ventures, with additional investments from Invus Capital and leaders in oncology from across the globe.
- The company, previously incubated by BeiGene (NASDAQ: BGNE), aims to revolutionize access to innovative cancer treatments through its technology platform and global network of clinical trial sites.
Less Than 8% of
Read More
Zetaris Unveils AI Studio for Disease Detection and Diagnosis
What You Should Know:
Zetaris, the provider of the AI-Powered Lakehouse, today unveils its game changing AI studio designed specifically for healthcare and life science professionals at the HIMSS Global Conference in Orlando on March 11-15, 2024.The Zetaris platform enables healthcare and life science professionals to develop life-saving patient outcomes enabled by data-driven AI clinical applications.
Empowering Healthcare Excellence: Zetaris Unveils Next-Generation AI Studio for
Read More
HIMSS24: Google Cloud Unveils New Generative AI Solutions for Healthcare and Life Sciences
What You Should Know:
- At HIMSS24, Google Cloud announced a suite of new generative AI solutions designed to address key challenges faced by healthcare and life sciences organizations.
- These solutions focus on improving interoperability, building a strong data foundation, and deploying generative AI (gen AI) tools to enhance patient outcomes.
Unlocking Gen AI to Improve Healthcare Efficiency
The healthcare industry is grappling with rising administrative costs, clinician burnout,
Read More
Israeli Life Science Industry Shows Resilience Despite Funding Slowdown
What You Should Know:
- The Israel Advanced Technologies Institute (IATI), in partnership with PwC and the Israel Innovation Authority, unveiled its annual Life Science Industry report at the MIXiii Health-Tech.IL conference.
- The report underlines the Israeli life sciences sector's resilience, unity, and determination to keep operating, innovating, and delivering crucial solutions. While acknowledging the current challenges, the research underscores the importance of continued support
Read More
